Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta
Open Access
- 11 March 2024
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 81 (2) , 248-257
Abstract
No abstract availableKeywords
Funding Information
- Medizinischen Hochschule Hannover
- Deutsche Forschungsgemeinschaft (ME 3696/3-1)
This publication has 30 references indexed in Scilit:
- Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)Wiener klinische Wochenschrift, 2023
- The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal HypertensionClinical Gastroenterology and Hepatology, 2022
- Non-invasive tests for clinically significant portal hypertension after HCV cureJournal of Hepatology, 2022
- Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertensionJournal of Hepatology, 2022
- Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and DeathClinical Gastroenterology and Hepatology, 2022
- Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosisUnited European Gastroenterology Journal, 2021
- EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 updateJournal of Hepatology, 2021
- The global prevalence of hepatitis D virus infection: Systematic review and meta-analysisJournal of Hepatology, 2020
- Clinical states of cirrhosis and competing risksJournal of Hepatology, 2018
- Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The “Anticipate” studyHepatology, 2016